BIVALIRUDIN Drug Interactions
Also known as: BIVALIRUDIN
Bivalirudin is an anticoagulant medication that helps prevent blood clots. It works by directly blocking a substance in the blood called thrombin, which is essential for clot formation. This medication is primarily used during a heart procedure called percutaneous coronary intervention (PCI), especially for patients who cannot use heparin due to a specific blood condition.BIVALIRUDIN has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with bivalirudin significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the heightened risk of serious bleeding events.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Bivalirudin is a direct thrombin inhibitor, preventing fibrin formation and platelet activation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
Patients are at a substantially increased risk of serious bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other site-specific bleeding. The risk of major bleeding can be several-fold higher compared to monotherapy, potentially leading to hospitalization, transfusions, or even fatal outcomes. This combination should generally be avoided. If both agents are absolutely necessary, carefully weigh the benefits against the profound bleeding risks, use the lowest effective doses for the shortest duration, and monitor closely for any signs of bleeding. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids, if appropriate. Regular monitoring of hemoglobin and hematocrit is crucial.
Combining Etodolac with Bivalirudin significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Etodolac, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Bivalirudin is a direct thrombin inhibitor, directly preventing clot formation. The combination leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal vulnerability.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding events. Patients may experience bruising, nosebleeds, blood in urine or stool, or severe abdominal pain. The risk of major bleeding is substantially elevated compared to either drug alone. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding, and the lowest effective dose of Etodolac for the shortest duration should be used. Consider alternative pain management strategies or alternative anticoagulants with lower bleeding risk if clinically appropriate. Gastroprotective agents (e.g., PPIs) may be considered but do not eliminate the risk.
Combining aspirin with bivalirudin significantly increases your risk of bleeding, including serious internal bleeding. Your healthcare provider will carefully weigh the benefits and risks of this combination.
Mechanism
Aspirin exerts antiplatelet effects by irreversibly inhibiting cyclooxygenase-1 (COX-1), preventing thromboxane A2 formation and platelet aggregation. Bivalirudin is a direct thrombin inhibitor, preventing thrombin's role in fibrin formation and platelet activation. The concurrent use leads to additive inhibition of primary hemostasis and coagulation cascade, profoundly increasing bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, which can range from minor bruising and epistaxis to major hemorrhage, including gastrointestinal bleeding, intracranial hemorrhage, or retroperitoneal bleeding. The risk of major bleeding with dual antiplatelet therapy (like aspirin) and an anticoagulant can be several-fold higher compared to anticoagulant monotherapy. This combination should be avoided if possible due to the high bleeding risk. If concurrent use is deemed absolutely necessary (e.g., during percutaneous coronary intervention), patients must be closely monitored for signs of bleeding, and the duration of dual therapy should be minimized. Dose adjustments of one or both agents may be considered, and proton pump inhibitors may be co-administered to reduce gastrointestinal bleeding risk.
Combining ibuprofen with bivalirudin significantly increases your risk of bleeding, including serious internal bleeding. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Ibuprofen, an NSAID, inhibits platelet aggregation and can cause gastrointestinal irritation and ulceration. Bivalirudin, a direct thrombin inhibitor, prevents clot formation. The combined effect of impaired platelet function and reduced coagulation, along with potential GI mucosal damage from ibuprofen, leads to a heightened risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor bruising or nosebleeds to severe, life-threatening gastrointestinal hemorrhage, intracranial bleeding, or other major bleeding events. Studies suggest that combining NSAIDs with anticoagulants can increase the risk of GI bleeding by 3 to 15 times. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine, severe headache). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is absolutely necessary, use the lowest effective dose for the shortest duration possible, and consider a proton pump inhibitor for GI protection.
Taking indomethacin, an anti-inflammatory pain reliever, with bivalirudin, a blood thinner, significantly increases your risk of serious bleeding. This combination should generally be avoided.
Mechanism
Indomethacin inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation, thereby increasing bleeding risk. Bivalirudin is a direct thrombin inhibitor, which prevents clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding potential.
Clinical Management
The primary clinical effect is an increased risk of bleeding, which can range from minor (e.g., bruising, nosebleeds) to severe and life-threatening (e.g., gastrointestinal bleeding, intracranial hemorrhage). The risk of gastrointestinal bleeding with NSAIDs combined with anticoagulants can be 3 to 15 times higher than with anticoagulants alone. This combination should be avoided if possible. If concomitant use is absolutely necessary, patients must be closely monitored for signs of bleeding, and the lowest effective doses of both medications should be used for the shortest duration. Consider alternative pain management strategies or alternative anticoagulants if feasible. Proton pump inhibitors may be considered to reduce GI bleeding risk.
Combining celecoxib with bivalirudin significantly increases your risk of bleeding, including serious internal bleeding. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa, increasing the risk of bleeding. Bivalirudin is a direct thrombin inhibitor, which directly interferes with the coagulation cascade. The concurrent use leads to an additive pharmacodynamic effect, significantly increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., melena, hematemesis), hematuria, epistaxis, bruising, or even intracranial hemorrhage. The risk of serious GI bleeding can be several-fold higher compared to either drug alone. Concurrent use should generally be avoided due to the high bleeding risk. If co-administration is deemed absolutely necessary, it should be done with extreme caution, very close monitoring for signs of bleeding, and the lowest effective doses for the shortest possible duration. Consider alternative pain management strategies that do not increase bleeding risk.
Combining piroxicam with bivalirudin significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Bivalirudin is a direct thrombin inhibitor that prevents fibrin formation and platelet activation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially elevated risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., ulcers, melena, hematemesis), intracranial hemorrhage, hematuria, or other serious hemorrhagic events. The risk of major bleeding can be several-fold higher compared to monotherapy, potentially leading to hospitalization, transfusions, or even death. This combination should be avoided due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternatives with lower systemic absorption (e.g., topical NSAIDs) or alternative pain management strategies. Close monitoring for signs of bleeding is essential if co-administration cannot be avoided, and bivalirudin dose adjustments may be necessary. Consider gastric protection with a proton pump inhibitor.
Combining meloxicam (an NSAID) with bivalirudin (an anticoagulant) significantly increases your risk of serious bleeding. This combination should generally be avoided.
Mechanism
Meloxicam inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa, increasing the risk of bleeding. Bivalirudin directly inhibits thrombin, preventing clot formation. The concurrent use of these agents leads to additive antihemostatic effects, synergistically increasing the likelihood of hemorrhage.
Clinical Management
This interaction significantly elevates the risk of major bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other site-specific bleeding. The risk of GI bleeding can be 3-15 times higher compared to anticoagulant monotherapy, potentially leading to severe complications requiring hospitalization or blood transfusions. Concurrent use of meloxicam and bivalirudin should be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or agents with a lower bleeding risk profile, such as acetaminophen. Closely monitor for any signs of bleeding (e.g., black/tarry stools, unusual bruising, epistaxis) if co-administration cannot be avoided, and use the lowest effective dose for the shortest duration.
Taking diclofenac with bivalirudin significantly increases your risk of bleeding, especially in the stomach or intestines. You should generally avoid this combination.
Mechanism
Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Bivalirudin is a direct thrombin inhibitor, preventing clot formation. The combined antiplatelet and anticoagulant effects, along with gastrointestinal mucosal damage from diclofenac, lead to an additive increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding events. This combination can increase the risk of serious bleeding events by 3 to 15 times compared to anticoagulant monotherapy, depending on the specific NSAID and patient risk factors. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective inhibitor with proton pump inhibitor co-therapy, under strict monitoring. Closely monitor for any signs of bleeding (e.g., black stools, unusual bruising, prolonged bleeding from minor cuts) and hemoglobin levels. Reassess the need for both medications frequently.
Combining ketorolac (an NSAID) with bivalirudin (an anticoagulant) significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Ketorolac inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Bivalirudin is a direct thrombin inhibitor that prevents fibrin formation and thrombus growth. The concurrent use of these agents results in additive antihemostatic effects, significantly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor events like bruising or nosebleeds to severe and life-threatening hemorrhages, including gastrointestinal, intracranial, or retroperitoneal bleeding. The risk of major bleeding is significantly elevated compared to either agent alone. This combination is generally contraindicated due to the high risk of severe bleeding. If co-administration is unavoidable, extreme caution and close monitoring for signs of bleeding are essential. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If NSAID use is absolutely necessary, use the lowest effective dose for the shortest duration possible and discontinue bivalirudin if clinically feasible.
For complete prescribing information:
View full BIVALIRUDIN monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.